Up 57% since June: this AI-picked pharma stock keeps climbing

In the span of four months, the AI-picked pharmaceutical stock Amneal Pharmaceuticals (NASDAQGS:AMRX) has surged by 57.75%, according to Investing.com. The stock was initially selected by the company's AI models back on June 1, 2026, and members who acted on the signal have been rewarded with a significant gain. Since the pick date, the stock has seen a 57.75% increase, despite weathering an initial post-earnings dip.

This performance has been bolstered by two key catalysts: the FDA approval of lanreotide injection and Amneal's Q2 2026 earnings report. The Q2 earnings report delivered an adjusted EPS of $0.30, surpassing the consensus of $0.23 by 30.4%, against revenue of $796.2 million. The FDA approval of lanreotide injection added further credibility to the stock's performance.

As of this month's review, the stock trades at 96.2% of its 52-week high, indicating a position of sustained strength. Over the past year and a half since the AI model's launch, the Mid-Cap Movers strategy, which includes Amneal Pharmaceuticals, has outperformed the S&P Midcap 400 by 48.5 percentage points.